0	10	Inhibition	Inhibition	NNP
11	13	of	of	IN
14	19	human	human	JJ
20	36	immunodeficiency	immunodeficiency	NN
37	42	virus	virus	NN
43	47	type	type	NN
48	49	1	1	CD
50	61	replication	replication	NN
62	64	in	in	FW
65	70	vitro	vitro	FW
71	73	by	by	IN
74	75	a	a	DT
76	81	novel	novel	JJ
82	93	combination	combination	NN
94	96	of	of	IN
97	105	anti-Tat	anti-tat	JJ
106	118	single-chain	single-chain	JJ
119	130	intrabodies	intrabody	NNS
131	134	and	and	CC
135	143	NF-kappa	NF-kappa	NNP
144	145	B	B	NNP
146	157	antagonists	antagonist	NNS
157	158	.	.	.

160	165	Human	human	JJ
166	182	immunodeficiency	immunodeficiency	NN
183	188	virus	virus	NN
189	193	type	type	NN
194	195	1	1	CD
196	197	(	(	(
197	202	HIV-1	HIV-1	NNP
202	203	)	)	)
204	207	Tat	Tat	NNP
207	208	,	,	,
209	211	an	an	DT
212	217	early	early	JJ
218	228	regulatory	regulatory	JJ
229	236	protein	protein	NN
237	241	that	that	WDT
242	244	is	be	VBZ
245	253	critical	critical	JJ
254	257	for	for	IN
258	263	viral	viral	JJ
264	268	gene	gene	NN
269	279	expression	expression	NN
280	283	and	and	CC
284	295	replication	replication	NN
295	296	,	,	,
297	311	transactivates	transactivate	VBZ
312	315	the	the	DT
316	321	HIV-1	HIV-1	NNP
322	326	long	long	JJ
327	335	terminal	terminal	JJ
336	342	repeat	repeat	NN
343	344	(	(	(
344	347	LTR	LTR	NNP
347	348	)	)	)
349	352	via	via	IN
353	356	its	its	PRP$
357	364	binding	binding	NN
365	367	to	to	TO
368	371	the	the	DT
372	387	transactivation	transactivation	NN
388	396	response	response	NN
397	404	element	element	NN
405	406	(	(	(
406	409	TAR	TAR	NNP
409	410	)	)	)
411	414	and	and	CC
414	415	,	,	,
416	421	along	along	IN
422	426	with	with	IN
427	432	other	other	JJ
433	441	cellular	cellular	JJ
442	449	factors	factor	NNS
449	450	,	,	,
451	460	increases	increase	VBZ
461	466	viral	viral	JJ
467	480	transcription	transcription	NN
481	491	initiation	initiation	NN
492	495	and	and	CC
496	506	elongation	elongation	NN
506	507	.	.	.

508	511	Tat	Tat	NNP
512	516	also	also	RB
517	531	superactivates	superactivate	VBZ
532	535	the	the	DT
536	541	HIV-1	HIV-1	NNP
542	550	promoter	promoter	NN
551	558	through	through	IN
559	560	a	a	DT
561	576	TAR-independent	tar-independent	JJ
577	586	mechanism	mechanism	NN
586	587	,	,	,
588	597	including	include	VBG
598	603	tumor	tumor	NN
604	612	necrosis	necrosis	NN
613	619	factor	factor	NN
620	633	alpha-induced	alpha-induced	JJ
634	637	and	and	CC
638	645	protein	protein	NN
646	652	kinase	kinase	NNP
653	654	C	C	NNP
655	656	(	(	(
656	670	PKC)-dependent	pkc)-dependent	JJ
671	681	activation	activation	NN
682	684	of	of	IN
685	693	NF-kappa	NF-kappa	NNP
694	695	B	B	NNP
695	696	,	,	,
697	700	and	and	CC
701	711	inhibitors	inhibitor	NNS
712	714	of	of	IN
715	718	Tat	Tat	NNP
719	722	and	and	CC
723	731	NF-kappa	NF-kappa	NNP
732	733	B	B	NNP
734	747	cooperatively	cooperatively	RB
748	761	down-regulate	down-regulate	VBP
762	766	this	this	DT
767	779	Tat-mediated	tat-mediated	JJ
780	783	LTR	LTR	NNP
784	799	superactivation	superactivation	NN
799	800	.	.	.

801	803	In	in	IN
804	808	this	this	DT
809	814	study	study	NN
814	815	,	,	,
816	817	a	a	DT
818	826	combined	combined	JJ
827	840	pharmacologic	pharmacologic	JJ
841	844	and	and	CC
845	852	genetic	genetic	JJ
853	861	strategy	strategy	NN
862	867	using	use	VBG
868	871	two	two	CD
872	875	PKC	PKC	NNP
876	877	(	(	(
877	885	NF-kappa	NF-kappa	NNP
886	887	B	B	NNP
887	888	)	)	)
889	899	inhibitors	inhibitor	NNS
899	900	,	,	,
901	915	pentoxifylline	pentoxifylline	NN
916	917	(	(	(
917	920	PTX	PTX	NNP
920	921	)	)	)
922	925	and	and	CC
926	933	Go-6976	Go-6976	NNP
933	934	,	,	,
935	938	and	and	CC
939	940	a	a	DT
941	947	stably	stably	RB
948	957	expressed	express	VBN
958	966	anti-Tat	anti-tat	JJ
967	979	single-chain	single-chain	JJ
980	993	intracellular	intracellular	JJ
994	1002	antibody	antibody	NN
1003	1004	(	(	(
1004	1007	sFv	sfv	NN
1008	1017	intrabody	intrabody	NN
1017	1018	)	)	)
1019	1022	was	be	VBD
1023	1031	employed	employ	VBN
1032	1034	to	to	TO
1035	1041	obtain	obtain	VB
1042	1053	cooperative	cooperative	JJ
1054	1064	inhibition	inhibition	NN
1065	1067	of	of	IN
1068	1072	both	both	CC
1073	1078	HIV-1	HIV-1	NNP
1079	1089	LTR-driven	ltr-driven	JJ
1090	1094	gene	gene	NN
1095	1105	expression	expression	NN
1106	1109	and	and	CC
1110	1115	HIV-1	HIV-1	NNP
1116	1127	replication	replication	NN
1127	1128	.	.	.

1129	1138	Treatment	Treatment	NNP
1139	1141	of	of	IN
1142	1147	cells	cell	NNS
1148	1152	with	with	IN
1153	1156	PTX	PTX	NNP
1157	1160	and	and	CC
1161	1168	Go-6976	Go-6976	NNP
1169	1177	resulted	result	VBD
1178	1180	in	in	IN
1181	1192	cooperative	cooperative	JJ
1193	1203	inhibition	inhibition	NN
1204	1206	of	of	IN
1207	1211	both	both	CC
1212	1217	HIV-1	HIV-1	NNP
1218	1228	LTR-driven	ltr-driven	JJ
1229	1233	gene	gene	NN
1234	1244	expression	expression	NN
1245	1248	and	and	CC
1249	1254	HIV-1	HIV-1	NNP
1255	1266	replication	replication	NN
1266	1267	.	.	.

1268	1270	In	in	IN
1271	1279	addition	addition	NN
1279	1280	,	,	,
1281	1284	the	the	DT
1285	1293	combined	combined	JJ
1294	1297	use	use	NN
1298	1300	of	of	IN
1301	1309	anti-Tat	anti-tat	JJ
1310	1313	sFv	sfv	NN
1314	1325	intrabodies	intrabody	NNS
1326	1329	and	and	CC
1330	1333	the	the	DT
1334	1337	two	two	CD
1338	1346	NF-kappa	NF-kappa	NNP
1347	1348	B	B	NNP
1349	1359	inhibitors	inhibitor	NNS
1360	1368	retained	retain	VBD
1369	1372	the	the	DT
1373	1378	virus	virus	NN
1379	1381	in	in	IN
1382	1385	the	the	DT
1386	1392	latent	latent	JJ
1393	1398	state	state	NN
1399	1402	for	for	IN
1403	1405	as	as	RB
1406	1410	long	long	JJ
1411	1413	as	as	IN
1414	1416	45	45	CD
1417	1421	days	day	NNS
1421	1422	.	.	.

1423	1426	The	the	DT
1427	1435	combined	combined	JJ
1436	1445	treatment	treatment	NN
1446	1454	resulted	result	VBD
1455	1457	in	in	IN
1458	1462	more	more	RBR
1463	1470	durable	durable	JJ
1471	1481	inhibition	inhibition	NN
1482	1484	of	of	IN
1485	1490	HIV-1	HIV-1	NNP
1491	1502	replication	replication	NN
1503	1507	than	than	IN
1508	1511	was	be	VBD
1512	1516	seen	see	VBN
1517	1521	with	with	IN
1522	1525	the	the	DT
1526	1534	NF-kappa	NF-kappa	NNP
1535	1536	B	B	NNP
1537	1547	inhibitors	inhibitor	NNS
1548	1553	alone	alone	RB
1554	1556	or	or	CC
1557	1560	the	the	DT
1561	1569	anti-Tat	anti-tat	JJ
1570	1573	sFv	sfv	NN
1574	1585	intrabodies	intrabody	NNS
1586	1591	alone	alone	RB
1591	1592	.	.	.

1593	1601	Together	together	RB
1601	1602	,	,	,
1603	1608	these	these	DT
1609	1616	results	result	NNS
1617	1624	suggest	suggest	VBP
1625	1629	that	that	IN
1630	1632	in	in	IN
1633	1639	future	future	JJ
1640	1648	clinical	clinical	JJ
1649	1653	gene	gene	NN
1654	1661	therapy	therapy	NN
1662	1668	trials	trial	NNS
1668	1669	,	,	,
1670	1671	a	a	DT
1672	1680	combined	combined	JJ
1681	1694	pharmacologic	pharmacologic	JJ
1695	1698	and	and	CC
1699	1706	genetic	genetic	JJ
1707	1715	strategy	strategy	NN
1716	1720	like	like	IN
1721	1724	the	the	DT
1725	1728	one	one	CD
1729	1737	reported	report	VBN
1738	1742	here	here	RB
1743	1746	may	may	MD
1747	1754	improve	improve	VB
1755	1758	the	the	DT
1759	1767	survival	survival	NN
1768	1770	of	of	IN
1771	1781	transduced	transduce	VBN
1782	1787	cells	cell	NNS
1788	1791	and	and	CC
1792	1799	prolong	prolong	VB
1800	1808	clinical	clinical	JJ
1809	1816	benefit	benefit	NN
1816	1817	.	.	.